{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:45:42Z","timestamp":1780677942419,"version":"3.54.1"},"reference-count":24,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Patient Care and STDs"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>\n                    Use of two-drug regimens (2DR) can reduce lifetime exposure to antiretroviral drugs while maintaining viral suppression. We aim to assess the real-life durability of 2DR in treatment-experienced people living with HIV (PLWH) who are virologically suppressed. We conducted a monocentric retrospective study in a referral center for PLWH in Northern France. PLWH who received 2DR as maintenance therapy (viral load &lt;50 copies\/mL at initiation) anytime between 1 January 2011 and 1 May 2023 were included. The duration of 2DR, reasons for and factors associated with switching to 3DR were analyzed. A total of 579 PLHIV were included. Dolutegravir (DTG) or ritonavir-boosted protease inhibitor (PI\/r)-based 2DR were the most frequently prescribed regimens, respectively, in 64% and 16% of cases. Sixty-nine patients (12%) received injectable long-acting cabotegravir-rilpivirine. Reasons for initiating 2DR were mainly drug reduction (61%). Median follow-up time on 2DR was 20.4 months (IQR: 7.9\u201336.4) with 110 patients (19%) switching to 3DR after a median duration of 10.1 months (IQR: 2.7\u201326.5). Sixteen patients returned to a 3DR because of virological failure leading to one new onset of resistance-associated mutation. 2DR durability was significantly longer with the DTG-based regimen (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    &lt; 0.0001). History of CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cell count &lt;200\/mm3 (HR: 1.64, 95% CI: [1.09\u20132.47],\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    = 0.018) and number of previous antiretroviral regimen (HR: 1.92, 95% CI: [1.74\u20132.12],\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    &lt; 0.001) were associated with a return to a 3DR. Our study showed that 2DR was a sustainable simplification strategy in a real-life setting. The return to 3DR was significantly impacted by the prescription of 2DR in patients heavily pre-treated.\n                  <\/jats:p>","DOI":"10.1177\/10872914251394849","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:00:12Z","timestamp":1762786812000},"page":"490-496","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Durability of Two-Drug Antiretroviral Regimens as Maintenance Therapy in People Living with HIV and Reasons for Switch to a Three-Drug Regimen: A Real-Life Cohort Study"],"prefix":"10.1177","volume":"39","author":[{"given":"Emmanuelle","family":"Bontemps","sequence":"first","affiliation":[{"name":"Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Meybeck","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Degrendel","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de recherche clinique, Centre Hospitalier de Tourcoing, Tourcoing, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Diarra","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macha","family":"Tetart","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Derdour","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enagnon Kazali","family":"Alidjinou","sequence":"additional","affiliation":[{"name":"Laboratoire de Virologie, CHU de Lille, Lille, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Robineau","sequence":"additional","affiliation":[{"name":"Service des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France."},{"name":"EA2694: METRICS, Univ Lille, Lille, France."},{"name":"INSERM u1136, Sorbonne Universit\u00e9, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,18]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00097-3"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00096-1"},{"issue":"4","key":"e_1_3_2_4_2","first-page":"1163","article-title":"Treatment simplification to atazanavir\/ritonavir\u2009+\u2009lamivudine versus maintenance of atazanavir\/ritonavir\u2009+\u2009two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)","volume":"72","author":"Di Giambenedetto S","year":"2017","unstructured":"Di Giambenedetto S, , Fabbiani M, , Quiros Roldan E, et al.; Atlas-M Study Group. Treatment simplification to atazanavir\/ritonavir\u2009+\u2009lamivudine versus maintenance of atazanavir\/ritonavir\u2009+\u2009two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother, 2017; 72(4):1163\u20131171.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix734"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00249-1"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00056-0"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32462-0"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1243"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac130"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac036"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32666-0"},{"key":"e_1_3_2_15_2","unstructured":"European AIDS Clinical Society Guidelines Version 12.0 Oct 2023. Available from: https:\/\/www.eacsociety.org\/media\/guidelines-12.0pdf [Last accessed: September16 2025]."},{"issue":"7","key":"e_1_3_2_16_2","first-page":"299","article-title":"NADIS 2000, development of an electronic medical record for patients infected by HIV, HBV and HCV","volume":"32","author":"Pugliese P","year":"2003","unstructured":"Pugliese P, , Cuzin L, , Enel P, et al. NADIS 2000, development of an electronic medical record for patients infected by HIV, HBV and HCV. Presse Med, 2003; 32(7):299\u2013303.","journal-title":"Presse Med"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003657"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3666-8"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/v15040936"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29149"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2022.07.022"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt536"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13647"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2024.0093"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003588"}],"container-title":["AIDS Patient Care and STDs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10872914251394849","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914251394849","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10872914251394849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:08:56Z","timestamp":1777399736000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10872914251394849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1177\/10872914251394849"],"URL":"https:\/\/doi.org\/10.1177\/10872914251394849","relation":{},"ISSN":["1087-2914","1557-7449"],"issn-type":[{"value":"1087-2914","type":"print"},{"value":"1557-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}